Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases Cover

.blurhash-client-img { display: none !important; }

Clinical and economic issues complicating cost-effectiveness evaluation of orphan diseases

The EuroBiotech Journal

Volume 1 (2017): Issue 2 (May 2017)

By: Mark J.C. Nuijten, Marja H. Pronk, John Hutton, Peter van Hasselt, Cor Oosterwijk and Frans F.H. Rutten

Open Access

|May 2017

Authors

Mark J.C. Nuijten

Mark J.C. Nuijten, MD, PhD, MBA, A2M,, Amsterdam, Netherlands

Marja H. Pronk

marja.pronk@mhpronk.nl

MD, Europe-ExPro,, Munich, Germany

John Hutton

BPhil, Health Economist, University of, York, United Kingdom of Great Britain and Northern Ireland

Peter van Hasselt

MD, PhD, Pediatrician for metabolic diseases, University Medical Centre, Utrecht, Netherlands

Cor Oosterwijk

PhD, Dutch Genetic Alliance (VSOP),, Soest, Netherlands

Frans F.H. Rutten

PhD, Health Economist, Institute for Medical Technology Assessment (iMTA), EUR, Rotterdam, United Kingdom of Great Britain and Northern Ireland

DOI: https://doi.org/10.24190/ISSN2564-615X/2017/02.04 | Journal eISSN: 2564-615X

Journal RSS Feed

Language: English

Page range: 132 - 137

Published on: May 9, 2017

Published by: European Biotechnology Thematic Network Association

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Related subjects:

Bioinformatics,

Life sciences, other

© 2017 Mark J.C. Nuijten, Marja H. Pronk, John Hutton, Peter van Hasselt, Cor Oosterwijk, Frans F.H. Rutten, published by European Biotechnology Thematic Network Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 1 (2017): Issue 2 (May 2017)Next article